IVBXF (Innovent Biologics) Total Stockholders Equity: $2,748 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IVBXF Innovent Biologics Inc IVBXF
77 GF Score
Price $14.72
GF Value $13.94
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Innovent Biologics Total Stockholders Equity?

Innovent Biologics IVBXF +3.66% 77 Total Stockholders Equity is $2,748 Mil as of Dec. 2025. GuruFocus rates IVBXF with a GF Score™ of 77/100 and a GF Value™ of $13.94 (Fairly Valued). The stock has 4 warning signs investors should review.

Innovent Biologics's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $2,748 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Innovent Biologics's Book Value per Share for the quarter that ended in Dec. 2025 was $1.58. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Innovent Biologics's Debt-to-Equity for the quarter that ended in Dec. 2025 was 0.15.

Innovent Biologics  (OTCPK:IVBXF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Innovent Biologics's Book Value per Share for the quarter that ended in Dec. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(2748.217-0)/1734.623
=1.58

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Innovent Biologics's Debt-to-Equity for the quarter that ended in Dec. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(113.613 + 286.173) / 2748.217
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovent Biologics Total Stockholders Equity Related Terms

Innovent Biologics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Innovent Biologics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovent Biologics Total Stockholders Equity Chart

Innovent Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,621.91 1,539.07 1,754.51 1,801.71 2,748.22

Innovent Biologics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,754.51 1,712.87 1,801.71 2,008.50 2,748.22
IVBXF
77GF Score
Innovent Biologics Inc IVBXF
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $2,748 Mil mean?
Innovent Biologics (IVBXF) has a Total Stockholders Equity of $2,748 Mil as of Dec. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Innovent Biologics and its competitors.
Is Innovent Biologics' Total Stockholders Equity too high?
Innovent Biologics' current Total Stockholders Equity is $2,748 Mil. Overall, Innovent Biologics has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Innovent Biologics' Total Stockholders Equity compare to VRTX and REGN?
Innovent Biologics' Total Stockholders Equity of $2,748 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Innovent Biologics and its competitors. Innovent Biologics's current Total Stockholders Equity is $2,748 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovent Biologics stock overvalued right now?
Based on GuruFocus' analysis, Innovent Biologics (IVBXF) is currently considered Fairly Valued. The stock's GF Value™ is $13.94, compared to a current price of $14.72 — trading 5.6% above its estimated fair value. The current Total Stockholders Equity is $2,748 Mil. Innovent Biologics' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Innovent Biologics (IVBXF), the current Total Stockholders Equity is $2,748 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Innovent Biologics (IVBXF) Overvalued in 2026?

Based on GuruFocus' analysis, Innovent Biologics stock appears to be overvalued. The current stock price of $14.72 is trading 5.6% above its estimated GF Value™ of $13.94. GuruFocus considers Innovent Biologics to be Fairly Valued.

Key valuation signals for IVBXF:

  • Total Stockholders Equity: $2,748 Mil
  • GF Value™: $13.94 vs. price of $14.72 (5.6% above fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the IVBXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Innovent Biologics Business Description

Address 168 Dongping Street, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215123
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
77GF Score

Get the complete analysis for IVBXF

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.72
Price
$13.94
GF Value